Biological therapies in osteoarthritis
Claire Y J Wenham, Michael McDermott, Philip G Conaghan1
1Leeds Institute of Rheumatic and Musculoskeletal Medicine, Chapel Allerton Hospital, Chapeltown Rd, Leeds LS7 4SA, UK. p.conaghan@leeds.ac.uk.
Abstract:
Given the paucity of effective therapies and the increasing prevalence of osteoarthritis (OA) with ageing and overweight populations, new therapies for this painful, life-impairing condition are desperately needed, for both symptom relief and structural modification. With a growing understanding that OA involves multiple tissue pathologies including inflammation, many more therapeutic targets have been identified. This review will provide a current overview on the role of biologics in OA, including anti-tumour necrosis factor agents, growth factors and interleukin-1 antagonists.
Insights
New biologic therapies are needed for osteoarthritis (OA) to address symptom relief and structural modification. This review explores anti-tumour necrosis factor agents, growth factors, and interleukin-1 antagonists as potential OA treatments.
Area of Science:
- Rheumatology
- Immunology
- Pharmacology
Background:
- Osteoarthritis (OA) is a prevalent, debilitating condition with limited effective treatments.
- Aging and overweight populations contribute to the rising incidence of OA.
- OA involves complex pathologies, including inflammation, necessitating novel therapeutic targets.
Purpose of the Study:
- To provide a comprehensive review of biologic therapies for osteoarthritis.
- To highlight emerging therapeutic targets within OA pathology.
- To discuss the potential of biologics for both symptom management and structural modification in OA.
Main Methods:
- Literature review of current research on biologic agents in OA.
- Analysis of therapeutic targets including inflammation pathways.
- Categorization of biologics such as anti-TNF agents, growth factors, and IL-1 antagonists.
Main Results:
- Biologic agents offer promising avenues for OA treatment.
- Targeting inflammation and other pathologies is key to developing effective OA therapies.
- Specific biologics like anti-tumour necrosis factor agents, growth factors, and interleukin-1 antagonists show potential.
Conclusions:
- Biologics represent a significant area of development for osteoarthritis therapeutics.
- Further research is warranted to optimize the use of biologics for OA symptom relief and structural repair.
- Targeting multiple OA pathologies with biologics may offer superior outcomes.
Related Concept Videos
01:29Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF